Literature DB >> 8587762

An evaluation of 99Tcm-DMSA SPET with three-dimensional reconstruction in 68 patients with varied renal pathology.

G J Cook1, M K Lewis, S E Clarke.   

Abstract

Sixty-eight patients (135 kidneys) with varied renal pathology were evaluated with 99Tcm-dimercaptosuccinic acid (DMSA) single photon emission tomography (SPET) to determine whether it is possible to detect more renal abnormalities and to reduce the number of false-positives due to anatomical variants when compared with planar imaging. The patients ranged in age from 1 to 78 years and their pathologies included urinary tract infection (n = 50), space occupying lesions (n = 5), calculi (n = 4), hypertension (n = 4) and others (n = 5). Planar scans were performed 3 h after the injection of 80 MBq of 99Tcm-DMSA and a 64 x 20 s acquisition over 360 degrees was used for SPET. High-resolution collimation was used for both. Slices were displayed as transaxial, coronal and sagittal and/or oblique sagittal in the plane of the kidney. Three-dimensional (3D) images were formed by volume rendering. Each kidney was divided into three regions and each region scored separately for the presence of an abnormality. Planar scans were reviewed alone and then in conjunction with SPET and 3D images. Planar imaging detected 95 abnormal regions compared with 103 using SPET. SPET reduced the number of equivocal regions in 8 (12%) patients. The diagnosis was altered by SPET in 17 (4%) regions in 14 (21%) patients. SPET and 3D 99Tcm-DMSA allow more abnormalities to be detected but also allow more specific definition of apparent abnormalities on planar imaging.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8587762     DOI: 10.1097/00006231-199511000-00012

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  1 in total

1.  Single-photon emission CT using (99m)Tc-dimercaptosuccinic acid (DMSA) for characterization of suspected renal masses.

Authors:  T Grüning; B E Drake; S J Freeman
Journal:  Br J Radiol       Date:  2014-05-16       Impact factor: 3.039

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.